Collegium Pharmaceutical, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Collegium Pharmaceutical, Inc. (COLL) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of 1.83% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2020-02-27
- Collegium Pharmaceutical, Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2019 was 1.83%, a 251.92% increase from fiscal 2018.
- Collegium Pharmaceutical, Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2018 was 0.52%, a 1.89% decline from fiscal 2017.
- Collegium Pharmaceutical, Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2017 was 0.53%, a 96.30% increase from fiscal 2016.
- Collegium Pharmaceutical, Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2016 was 0.27%, a 69.66% decline from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month |
|---|---|
| 2019-12-31 | 1.83% 10-K · filed 2020-02-27 |
| 2018-12-31 | 0.52% 10-K · filed 2020-02-27 |
| 2017-12-31 | 0.53% 10-K · filed 2020-02-27 |
| 2016-12-31 | 0.27% 10-K · filed 2019-02-27 |
| 2015-12-31 | 0.89% 10-K · filed 2018-03-07 |
| 2014-12-31 | 3.74% 10-K · filed 2017-03-10 |
| 2013-12-31 | 4.19% 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |